STOCK TITAN

[Form 3] Liquidia Corporation Initial Statement of Beneficial Ownership

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
3
Rhea-AI Filing Summary

Core Scientific, Inc. (CORZ) – Form 4 Insider Transaction filed 07/03/2025

The filing discloses a single transaction by Chief Executive Officer and Director Adam Taylor Sullivan occurring on 07/01/2025. The Form 4 uses transaction code “F”, indicating shares were withheld by the company to satisfy income-tax obligations triggered by the vesting of previously granted restricted stock units (RSUs). A total of 23,508 common shares were withheld at an indicated price of $17.07 per share. No cash proceeds were received by the insider, and the disposition represents less than 1% of his holdings.

After the withholding event, Mr. Sullivan continues to own 4,383,553 shares of Core Scientific common stock in direct form. Footnote 2 clarifies that this figure already includes 4,912 shares distributed in-kind to him on 09/19/2024 from XMS Core Convert Holdings LLC, a transaction previously exempt from Section 16 reporting.

The filing is routine and does not involve the exercise of options, open-market purchases, or sales that would materially affect the public float. It nevertheless confirms that the CEO maintains a sizable equity stake, aligning his incentives with shareholders. From a trading-signal perspective, the share withholding is neutral; it neither increases insider buying conviction nor indicates discretionary selling pressure.

Core Scientific, Inc. (CORZ) – Modulo 4 Transazione Insider presentata il 03/07/2025

La comunicazione rivela una singola operazione effettuata dal CEO e Direttore Adam Taylor Sullivan in data 01/07/2025. Il Modulo 4 utilizza il codice transazione “F”, che indica che le azioni sono state trattenute dalla società per coprire le imposte sul reddito derivanti dal consolidamento di unità azionarie vincolate (RSU) precedentemente assegnate. In totale sono state trattenute 23.508 azioni ordinarie ad un prezzo indicato di $17,07 per azione. L’insider non ha ricevuto alcun ricavo in contanti e la cessione rappresenta meno dell’1% delle sue partecipazioni.

Dopo questo evento di trattenuta, il Sig. Sullivan detiene ancora 4.383.553 azioni ordinarie di Core Scientific in forma diretta. La nota 2 chiarisce che questa cifra include già 4.912 azioni distribuite in natura il 19/09/2024 da XMS Core Convert Holdings LLC, una transazione precedentemente esente dalla segnalazione ai sensi della Sezione 16.

La comunicazione è di routine e non coinvolge l’esercizio di opzioni, acquisti sul mercato aperto o vendite che possano influenzare materialmente il flottante pubblico. Conferma comunque che il CEO mantiene una partecipazione azionaria significativa, allineando i suoi interessi con quelli degli azionisti. Dal punto di vista del segnale di trading, la trattenuta delle azioni è neutra; non aumenta la convinzione di acquisto insider né indica pressioni di vendita discrezionali.

Core Scientific, Inc. (CORZ) – Formulario 4 Transacción Insider presentado el 03/07/2025

La presentación revela una única transacción realizada por el Director Ejecutivo y Director Adam Taylor Sullivan ocurrida el 01/07/2025. El Formulario 4 utiliza el código de transacción “F”, que indica que la empresa retuvo acciones para cubrir obligaciones fiscales generadas por la consolidación de unidades restringidas de acciones (RSUs) previamente otorgadas. Se retuvieron un total de 23,508 acciones ordinarias a un precio indicado de $17.07 por acción. El insider no recibió ingresos en efectivo y la disposición representa menos del 1% de sus tenencias.

Después del evento de retención, el Sr. Sullivan sigue poseyendo 4,383,553 acciones ordinarias de Core Scientific en forma directa. La nota al pie 2 aclara que esta cifra ya incluye 4,912 acciones distribuidas en especie el 19/09/2024 desde XMS Core Convert Holdings LLC, una transacción previamente exenta de reporte bajo la Sección 16.

La presentación es rutinaria y no involucra el ejercicio de opciones, compras en mercado abierto o ventas que afectarían materialmente el flotante público. Sin embargo, confirma que el CEO mantiene una participación accionaria considerable, alineando sus incentivos con los accionistas. Desde la perspectiva de señales de trading, la retención de acciones es neutral; no aumenta la convicción de compra insider ni indica presión discrecional de venta.

Core Scientific, Inc. (CORZ) – 2025년 7월 3일 제출된 내부자 거래 Form 4

본 제출서는 최고경영자 겸 이사 Adam Taylor Sullivan2025년 7월 1일에 단일 거래를 수행했음을 공개합니다. Form 4는 거래 코드 “F”를 사용했으며, 이는 이전에 부여된 제한 주식 단위(RSU)의 권리 확정으로 인해 발생한 소득세 의무를 충당하기 위해 회사가 주식을 원천징수했음을 의미합니다. 총 23,508 보통주가 주당 $17.07의 가격으로 원천징수되었습니다. 내부자는 현금 수익을 받지 않았으며, 이번 처분은 그의 보유 지분의 1% 미만에 해당합니다.

원천징수 이후 Sullivan 씨는 직접 소유 형태로 Core Scientific 보통주 4,383,553주를 계속 보유하고 있습니다. 각주 2는 이 수치에 2024년 9월 19일 XMS Core Convert Holdings LLC로부터 현물로 배분된 4,912주가 이미 포함되어 있으며, 이는 이전에 섹션 16 보고에서 면제된 거래임을 명확히 합니다.

이번 제출은 일상적인 절차이며, 옵션 행사, 공개 시장 매수 또는 공공 유통 주식에 중대한 영향을 미칠 매도와 관련이 없습니다. 그럼에도 불구하고 CEO가 상당한 지분을 유지하고 있음을 확인시켜 주며, 이는 그의 동기를 주주와 일치시킵니다. 거래 신호 관점에서 볼 때, 주식 원천징수는 중립적이며 내부자 매수 확신을 높이거나 임의 매도 압력을 나타내지 않습니다.

Core Scientific, Inc. (CORZ) – Déclaration Formulaire 4 d’initié déposée le 03/07/2025

Le dépôt révèle une seule transaction effectuée par le Directeur Général et Administrateur Adam Taylor Sullivan le 01/07/2025. Le Formulaire 4 utilise le code de transaction « F », indiquant que des actions ont été retenues par la société pour satisfaire des obligations fiscales générées par l’acquisition définitive d’unités d’actions restreintes (RSU) précédemment attribuées. Un total de 23 508 actions ordinaires ont été retenues à un prix indiqué de 17,07 $ par action. L’initié n’a reçu aucun produit en espèces et cette disposition représente moins de 1 % de ses avoirs.

Après cet événement de retenue, M. Sullivan détient toujours 4 383 553 actions ordinaires de Core Scientific en forme directe. La note de bas de page 2 précise que ce chiffre inclut déjà 4 912 actions qui lui ont été distribuées en nature le 19/09/2024 par XMS Core Convert Holdings LLC, une transaction auparavant exemptée de déclaration en vertu de la Section 16.

Le dépôt est de routine et n’implique ni exercice d’options, ni achats sur le marché ouvert, ni ventes susceptibles d’affecter matériellement le flottant public. Il confirme néanmoins que le PDG conserve une participation importante, alignant ainsi ses intérêts avec ceux des actionnaires. Du point de vue du signal de trading, la retenue d’actions est neutre ; elle n’augmente ni la conviction d’achat des initiés ni ne signale une pression de vente discrétionnaire.

Core Scientific, Inc. (CORZ) – Form 4 Insider-Transaktion eingereicht am 03.07.2025

Die Einreichung offenbart eine einzelne Transaktion des CEO und Direktors Adam Taylor Sullivan am 01.07.2025. Das Form 4 verwendet den Transaktionscode „F“, was darauf hinweist, dass Aktien vom Unternehmen einbehalten wurden, um Einkommenssteuerverpflichtungen zu erfüllen, die durch die Vesting von zuvor gewährten Restricted Stock Units (RSUs) ausgelöst wurden. Insgesamt wurden 23.508 Stammaktien zu einem angegebenen Preis von 17,07 $ pro Aktie einbehalten. Der Insider erhielt keine Barauszahlung, und die Veräußerung macht weniger als 1 % seines Bestands aus.

Nach der Einbehaltung besitzt Herr Sullivan weiterhin 4.383.553 Aktien von Core Scientific in direkter Form. Fußnote 2 stellt klar, dass diese Zahl bereits 4.912 Aktien umfasst, die ihm am 19.09.2024 von XMS Core Convert Holdings LLC in natura zugeteilt wurden, eine Transaktion, die zuvor von der Meldepflicht nach Abschnitt 16 ausgenommen war.

Die Einreichung ist routinemäßig und beinhaltet weder die Ausübung von Optionen noch offene Markttransaktionen oder Verkäufe, die den Streubesitz wesentlich beeinflussen würden. Sie bestätigt jedoch, dass der CEO eine bedeutende Beteiligung hält, was seine Interessen mit denen der Aktionäre in Einklang bringt. Aus Handelssicht ist die Aktieneinbehaltung neutral; sie erhöht weder die Kaufüberzeugung von Insidern noch signalisiert sie einen diskretionären Verkaufsdruck.

Positive
  • CEO retains 4,383,553 common shares, reflecting a substantial alignment of interests with shareholders.
Negative
  • 23,508 shares were disposed (withheld for taxes), a minor 0.5% reduction in the CEO’s position.

Insights

TL;DR: Routine tax-withholding sale; CEO still holds 4.38 M shares; negligible impact on valuation or sentiment.

The reported 23,508-share disposition, executed under code “F,” is strictly an administrative step to cover withholding taxes on vested RSUs. At roughly $17 per share, the gross value is about $0.4 million—immaterial relative to Core Scientific’s average daily volume and the CEO’s residual 4.4 million-share stake. Because the shares never entered the open market, there is no incremental supply overhang. Investors should view the transaction as neutral; the CEO’s continued large holding suggests ongoing confidence.

TL;DR: Administrative disposition underscores compliance; insider ownership remains a robust governance positive.

Form 4 filings coded “F” often confuse investors, but they are mandated to ensure transparency when issuers net-settle RSUs. The CEO’s sizeable post-transaction stake (≈5–6% of shares outstanding, depending on current float) reinforces shareholder alignment. No red flags emerge: the filing is timely, complete, and includes proper power-of-attorney signature by the company’s counsel. As such, governance risk remains unchanged.

Core Scientific, Inc. (CORZ) – Modulo 4 Transazione Insider presentata il 03/07/2025

La comunicazione rivela una singola operazione effettuata dal CEO e Direttore Adam Taylor Sullivan in data 01/07/2025. Il Modulo 4 utilizza il codice transazione “F”, che indica che le azioni sono state trattenute dalla società per coprire le imposte sul reddito derivanti dal consolidamento di unità azionarie vincolate (RSU) precedentemente assegnate. In totale sono state trattenute 23.508 azioni ordinarie ad un prezzo indicato di $17,07 per azione. L’insider non ha ricevuto alcun ricavo in contanti e la cessione rappresenta meno dell’1% delle sue partecipazioni.

Dopo questo evento di trattenuta, il Sig. Sullivan detiene ancora 4.383.553 azioni ordinarie di Core Scientific in forma diretta. La nota 2 chiarisce che questa cifra include già 4.912 azioni distribuite in natura il 19/09/2024 da XMS Core Convert Holdings LLC, una transazione precedentemente esente dalla segnalazione ai sensi della Sezione 16.

La comunicazione è di routine e non coinvolge l’esercizio di opzioni, acquisti sul mercato aperto o vendite che possano influenzare materialmente il flottante pubblico. Conferma comunque che il CEO mantiene una partecipazione azionaria significativa, allineando i suoi interessi con quelli degli azionisti. Dal punto di vista del segnale di trading, la trattenuta delle azioni è neutra; non aumenta la convinzione di acquisto insider né indica pressioni di vendita discrezionali.

Core Scientific, Inc. (CORZ) – Formulario 4 Transacción Insider presentado el 03/07/2025

La presentación revela una única transacción realizada por el Director Ejecutivo y Director Adam Taylor Sullivan ocurrida el 01/07/2025. El Formulario 4 utiliza el código de transacción “F”, que indica que la empresa retuvo acciones para cubrir obligaciones fiscales generadas por la consolidación de unidades restringidas de acciones (RSUs) previamente otorgadas. Se retuvieron un total de 23,508 acciones ordinarias a un precio indicado de $17.07 por acción. El insider no recibió ingresos en efectivo y la disposición representa menos del 1% de sus tenencias.

Después del evento de retención, el Sr. Sullivan sigue poseyendo 4,383,553 acciones ordinarias de Core Scientific en forma directa. La nota al pie 2 aclara que esta cifra ya incluye 4,912 acciones distribuidas en especie el 19/09/2024 desde XMS Core Convert Holdings LLC, una transacción previamente exenta de reporte bajo la Sección 16.

La presentación es rutinaria y no involucra el ejercicio de opciones, compras en mercado abierto o ventas que afectarían materialmente el flotante público. Sin embargo, confirma que el CEO mantiene una participación accionaria considerable, alineando sus incentivos con los accionistas. Desde la perspectiva de señales de trading, la retención de acciones es neutral; no aumenta la convicción de compra insider ni indica presión discrecional de venta.

Core Scientific, Inc. (CORZ) – 2025년 7월 3일 제출된 내부자 거래 Form 4

본 제출서는 최고경영자 겸 이사 Adam Taylor Sullivan2025년 7월 1일에 단일 거래를 수행했음을 공개합니다. Form 4는 거래 코드 “F”를 사용했으며, 이는 이전에 부여된 제한 주식 단위(RSU)의 권리 확정으로 인해 발생한 소득세 의무를 충당하기 위해 회사가 주식을 원천징수했음을 의미합니다. 총 23,508 보통주가 주당 $17.07의 가격으로 원천징수되었습니다. 내부자는 현금 수익을 받지 않았으며, 이번 처분은 그의 보유 지분의 1% 미만에 해당합니다.

원천징수 이후 Sullivan 씨는 직접 소유 형태로 Core Scientific 보통주 4,383,553주를 계속 보유하고 있습니다. 각주 2는 이 수치에 2024년 9월 19일 XMS Core Convert Holdings LLC로부터 현물로 배분된 4,912주가 이미 포함되어 있으며, 이는 이전에 섹션 16 보고에서 면제된 거래임을 명확히 합니다.

이번 제출은 일상적인 절차이며, 옵션 행사, 공개 시장 매수 또는 공공 유통 주식에 중대한 영향을 미칠 매도와 관련이 없습니다. 그럼에도 불구하고 CEO가 상당한 지분을 유지하고 있음을 확인시켜 주며, 이는 그의 동기를 주주와 일치시킵니다. 거래 신호 관점에서 볼 때, 주식 원천징수는 중립적이며 내부자 매수 확신을 높이거나 임의 매도 압력을 나타내지 않습니다.

Core Scientific, Inc. (CORZ) – Déclaration Formulaire 4 d’initié déposée le 03/07/2025

Le dépôt révèle une seule transaction effectuée par le Directeur Général et Administrateur Adam Taylor Sullivan le 01/07/2025. Le Formulaire 4 utilise le code de transaction « F », indiquant que des actions ont été retenues par la société pour satisfaire des obligations fiscales générées par l’acquisition définitive d’unités d’actions restreintes (RSU) précédemment attribuées. Un total de 23 508 actions ordinaires ont été retenues à un prix indiqué de 17,07 $ par action. L’initié n’a reçu aucun produit en espèces et cette disposition représente moins de 1 % de ses avoirs.

Après cet événement de retenue, M. Sullivan détient toujours 4 383 553 actions ordinaires de Core Scientific en forme directe. La note de bas de page 2 précise que ce chiffre inclut déjà 4 912 actions qui lui ont été distribuées en nature le 19/09/2024 par XMS Core Convert Holdings LLC, une transaction auparavant exemptée de déclaration en vertu de la Section 16.

Le dépôt est de routine et n’implique ni exercice d’options, ni achats sur le marché ouvert, ni ventes susceptibles d’affecter matériellement le flottant public. Il confirme néanmoins que le PDG conserve une participation importante, alignant ainsi ses intérêts avec ceux des actionnaires. Du point de vue du signal de trading, la retenue d’actions est neutre ; elle n’augmente ni la conviction d’achat des initiés ni ne signale une pression de vente discrétionnaire.

Core Scientific, Inc. (CORZ) – Form 4 Insider-Transaktion eingereicht am 03.07.2025

Die Einreichung offenbart eine einzelne Transaktion des CEO und Direktors Adam Taylor Sullivan am 01.07.2025. Das Form 4 verwendet den Transaktionscode „F“, was darauf hinweist, dass Aktien vom Unternehmen einbehalten wurden, um Einkommenssteuerverpflichtungen zu erfüllen, die durch die Vesting von zuvor gewährten Restricted Stock Units (RSUs) ausgelöst wurden. Insgesamt wurden 23.508 Stammaktien zu einem angegebenen Preis von 17,07 $ pro Aktie einbehalten. Der Insider erhielt keine Barauszahlung, und die Veräußerung macht weniger als 1 % seines Bestands aus.

Nach der Einbehaltung besitzt Herr Sullivan weiterhin 4.383.553 Aktien von Core Scientific in direkter Form. Fußnote 2 stellt klar, dass diese Zahl bereits 4.912 Aktien umfasst, die ihm am 19.09.2024 von XMS Core Convert Holdings LLC in natura zugeteilt wurden, eine Transaktion, die zuvor von der Meldepflicht nach Abschnitt 16 ausgenommen war.

Die Einreichung ist routinemäßig und beinhaltet weder die Ausübung von Optionen noch offene Markttransaktionen oder Verkäufe, die den Streubesitz wesentlich beeinflussen würden. Sie bestätigt jedoch, dass der CEO eine bedeutende Beteiligung hält, was seine Interessen mit denen der Aktionäre in Einklang bringt. Aus Handelssicht ist die Aktieneinbehaltung neutral; sie erhöht weder die Kaufüberzeugung von Insidern noch signalisiert sie einen diskretionären Verkaufsdruck.

SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Boyle Dana

(Last) (First) (Middle)
419 DAVIS DRIVE, SUITE 100

(Street)
MORRISVILLE NC 27560

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
07/01/2025
3. Issuer Name and Ticker or Trading Symbol
Liquidia Corp [ LQDA ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Accounting Officer
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock 163,361(1)(2) D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Performance Stock Units (3) (3) Common Stock 50,861 (3) D
Stock Option (Right to Buy) 02/22/2025 02/22/2031 Common Stock 50,000 $3.44 D
Stock Option (Right to Buy) (4) 07/21/2031 Common Stock 10,000 $2.54 D
Stock Option (Right to Buy) (5) 01/16/2032 Common Stock 30,150 $6.25 D
Stock Option (Right to Buy) (6) 07/28/2032 Common Stock 25,000 $5.12 D
Explanation of Responses:
1. Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. 25% of the RSUs shall vest approximately one-year after the grant date of such RSUs and the remaining RSUs shall vest ratably on a quarterly basis over three years thereafter. Includes (i) 2,826 unvested RSUs of the 15,075 RSUs granted to the Reporting Person on January 16, 2022, (ii) 21,875 unvested RSUs of the 50,000 RSUs granted to the Reporting Person on January 25, 2023, (iii) 39,245 unvested RSUs of the 57,085 RSUs granted to the Reporting Person on January 11, 2024, (iv) 50,861 RSUs granted to the Reporting Person on January 11, 2025, none of which have vested as of July 1, 2025 and (v) 11,029 shares acquired under the Liquidia Corporation 2020 Employee Stock Purchase Plan.
2. Excludes an aggregate of 20,689 shares of common stock that were sold to cover taxes associated with the settlement of RSUs that were initially granted to the Reporting Person on January 16, 2022, January 23, 2023, and January 11, 2024.
3. Performance stock units ("PSUs") convert into common stock on a one-for-one basis. On January 11, 2025, the Reporting Person was granted 50,861 PSUs which vest upon the following time-based vesting schedule: 25% of the PSUs shall vest on January 11, 2026 and the remaining PSUs shall vest ratably on a quarterly basis over three years thereafter. No PSUs have vested as of July 1, 2025.
4. The option vests over a four-year period with 25% of the shares of common stock underlying the option vesting on the one-year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter, becoming fully vested on July 21, 2025.
5. The option vests in equal monthly installments over a four-year period, becoming fully vested on January 31, 2026.
6. The option vests in equal monthly installments over a four-year period, becoming fully vested on July 28, 2026.
By: /s/ Dana Boyle 07/03/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Core Scientific (CORZ) shares does CEO Adam Sullivan now own?

Following the 07/01/2025 transaction, he directly owns 4,383,553 common shares.

Was the July 2025 insider transaction an open-market sale?

No. Code “F” indicates shares were withheld to cover taxes; no open-market activity occurred.

What price was used for the share withholding on 07/01/2025?

The shares were valued at $17.07 per share for withholding purposes.

Does the filing suggest the CEO is selling Core Scientific stock?

The disposition is administrative and not a discretionary sale, so it carries neutral signaling value.

Why does the Form 4 reference 4,912 shares received in September 2024?

Footnote 2 notes those shares were an in-kind distribution from XMS Core Convert Holdings LLC, already included in his total ownership.
Liquidia Corporation

NASDAQ:LQDA

LQDA Rankings

LQDA Latest News

LQDA Latest SEC Filings

LQDA Stock Data

1.10B
71.79M
13.88%
61.4%
13.32%
Biotechnology
Pharmaceutical Preparations
Link
United States
MORRISVILLE